Literature DB >> 32399281

Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategies-a single institution experience.

Tuyen Hoang1, Michelle Park2, Darryl Hiyama3, Farshid Dayyani4.   

Abstract

BACKGROUND: While gastric cancer is a leading cause of cancer-related mortality in Eastern Europe and Asia, it is less common in the United States. Recommendations regarding optimal treatment of non-metastatic gastric cancer with regard to type and extent of surgery, choice and sequence of chemotherapeutic agents, and use of radiation therapy vary somewhat depending on geographic location. There is paucity in the literature for direct comparison of various practices. To determine how variability in treatment practices affects patient outcomes, we conducted a retrospective study in patients with gastric cancer who had multimodality treatment for non-metastatic gastric cancer.
METHODS: We gathered clinical data (patient demographics, pathology reports, type of surgical intervention, chemotherapy, and radiation therapy) for patients diagnosed with gastric adenocarcinoma who underwent gastrectomy at five sites from 2010-2017 using Electronic Health Records and California Cancer Registry databases. Medical chart reviews were conducted to validate patient outcomes. We performed multivariate Cox regression analyses to determine predictors for cancer recurrence and survival. We also performed logistic regression analyses to determine predictors of positive resection margins and hospitalization.
RESULTS: One hundred and sixteen patients met eligibility criteria to be included. Mean age was 65.7±11.6 years. About 65.5% were male. The most common ethnicities were Asian (44.0%) and Caucasian (37.9%). About 58.6% of the patients had localized disease (defined as pT1-3, pN0) and the remaining 41.4% had loco-regional disease (i.e., pT4 or pN+). About 41.4% of the tumors were diffuse, 27.6% intestinal, 12.0% mixed, and 19.0% unknown histology. Surgery included laparoscopic (94.8%) and open gastrectomy (5.2%). Chemotherapy and radiation therapy were given in 51.7% and 19.0% of the patients, respectively. After a median follow-up time of 19 months after gastrectomy, 16.4% of patients had recurrence and 19.8% had died. Patients who had loco-regional tumors were more likely to have recurrence and death than those who had localized tumors (hazard ratios =7.0, P=0.0228 for recurrence and hazard ratios =3.3, P=0.0160 for death). Positive resection margins were seen in 9% of the patients and were associated with diffuse histology (odds ratio =6.6, P=0.0207). Hospitalization within six months of gastrectomy was seen in 22% of the patients. Peri-operative chemotherapy was the only significant predictor for re-hospitalization (odds ratio =3.5, P=0.0415).
CONCLUSIONS: In this contemporary cohort of patients with localized gastric cancer, only the pathological stage was significantly associated with survival while positive resection margins were associated with diffuse histology. Closer monitoring of patients undergoing perioperative chemotherapy within 6 months of surgery is warranted based on our observation of higher rate of re-hospitalization. 2020 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Gastric cancer; gastrectomy; multimodality treatment; prognostic factors

Year:  2020        PMID: 32399281      PMCID: PMC7212096          DOI: 10.21037/jgo.2019.01.08

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  14 in total

1.  Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients.

Authors:  M S Karpeh; L Leon; D Klimstra; M F Brennan
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

2.  Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage.

Authors:  Roderich E Schwarz; David D Smith
Journal:  Ann Surg Oncol       Date:  2006-11-09       Impact factor: 5.344

3.  Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

Authors:  Annemieke Cats; Edwin P M Jansen; Nicole C T van Grieken; Karolina Sikorska; Pehr Lind; Marianne Nordsmark; Elma Meershoek-Klein Kranenbarg; Henk Boot; Anouk K Trip; H A Maurits Swellengrebel; Hanneke W M van Laarhoven; Hein Putter; Johanna W van Sandick; Mark I van Berge Henegouwen; Henk H Hartgrink; Harm van Tinteren; Cornelis J H van de Velde; Marcel Verheij
Journal:  Lancet Oncol       Date:  2018-04-09       Impact factor: 41.316

4.  Comparison of staging between the old (6th edition) and new (7th edition) TNM classifications in advanced gastric cancer.

Authors:  Shiro Kikuchi; Nobue Futawatari; Shinichi Sakuramoto; Natsuya Katada; Keishi Yamashita; Tomotaka Shibata; Masayuki Nemoto; Masahiko Watanabe
Journal:  Anticancer Res       Date:  2011-06       Impact factor: 2.480

5.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

6.  Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.

Authors:  Se Hoon Park; Tae Sung Sohn; Jeeyun Lee; Do Hoon Lim; Min Eui Hong; Kyoung-Mee Kim; Insuk Sohn; Sin Ho Jung; Min Gew Choi; Jun Ho Lee; Jae Moon Bae; Sung Kim; Seung Tae Kim; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang
Journal:  J Clin Oncol       Date:  2015-01-05       Impact factor: 44.544

7.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.

Authors:  Ilfet Songun; Hein Putter; Elma Meershoek-Klein Kranenbarg; Mitsuru Sasako; Cornelis J H van de Velde
Journal:  Lancet Oncol       Date:  2010-04-19       Impact factor: 41.316

8.  Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

Authors:  Charles S Fuchs; Donna Niedzwiecki; Harvey J Mamon; Joel E Tepper; Xing Ye; Richard S Swanson; Peter C Enzinger; Daniel G Haller; Tomislav Dragovich; Steven R Alberts; Georg A Bjarnason; Christopher G Willett; Leonard L Gunderson; Richard M Goldberg; Alan P Venook; David Ilson; Eileen O'Reilly; Kristen Ciombor; David J Berg; Jeffrey Meyerhardt; Robert J Mayer
Journal:  J Clin Oncol       Date:  2017-10-04       Impact factor: 44.544

9.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

10.  Does resection line involvement affect prognosis in early gastric cancer patients? An Italian multicentric study.

Authors:  Paolo Morgagni; Domenico Garcea; Daniele Marrelli; Giovanni de Manzoni; Giovanni Natalini; Hayato Kurihara; Alberto Marchet; Giovanni Vittimberga; Luca Saragoni; Franco Roviello; Alberto Di Leo; Francesco De Santis; Valerio Panizza; Donato Nitti
Journal:  World J Surg       Date:  2006-04       Impact factor: 3.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.